Close
Close
Treatment News

Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

3.0
3.0 from 2 votes
Monday, April 15, 2019

 

CAMBRIDGE, Mass.- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place April 29-May 2, 2019, in Washington, D.C. Data at this year’s meeting includes five oral presentations and seven poster presentations related to Voyager’s preclinical programs, including new data related to its vectorized antibody program directed against tau for the potential treatment of Alzheimer’s disease, VY-SOD102 targeting a monogenic form of Amyotrophic Lateral Sclerosis (ALS) called SOD1, VY-HTT01 for Huntington’s disease, as well as its adeno-associated virus (AAV) capsid development efforts and manufacturing capabilities. 

Details on all abstracts accepted for presentation can be found here through ASGCT’s online planner.

Titles, dates, local times and locations for Voyager Therapeutics’ oral presentations:

Title: “Cell Specific Transduction of a Vectorized Anti-Tau Antibody Using IV Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mice”
Session: Tools, Delivery and Neuro Capsids
Date/time: Monday, April 29, 2019, 11:00 a.m.
Location: Monroe

Title: “Intraparenchymal Spinal Cord Delivery of AAV Gene Therapy Provides Robust SOD1 Knockdown in Large Mammal Spinal Cord for the Treatment of SOD1-ALS”
Session: Tools, Delivery and Neuro Capsids
Date/time: Monday, April 29, 2019, 11:30 a.m.
Location: Monroe

Title: “Targeted in vivo Biopanning of AAV Capsid Libraries Using Cell Type-Specific RNA Expression”
Session: Directed Evolution of AAV Vectors I
Date/time: Monday, April 29, 2019, 11:45 a.m.
Location: Georgetown

Title: “Significant Reduction of Huntingtin Gene Expression in Cortex, Putamen and Caudate of Large Mammals with Combined Putamen and Thalamus Infusions of VY-HTT01, an AAV Gene Therapy Targeting Huntingtin for the Treatment of Huntington’s Disease”
Session: Gene Silencing Approaches
Date/time: Monday, April 29, 2019, 11:45 a.m.
Location: IBR West

Title: “Evaluation of Tropism and Transduction Efficiency of AAV Variants in the CNS of NHP using DNA/RNA Barcode-Seq Technology”
Session: Rational Engineering of AAV Vectors II
Date/time: Tuesday, April 30, 2019, 5:00 p.m.
Location: Georgetown

Titles, dates, local times and locations for Voyager Therapeutics’ poster presentations:

Title: “Multiple Novel Engineered AAV Capsids Demonstrate Enhanced Brain and Spinal Cord Gene Transfer After Systemic Administration in Adult Mice”
Session: Neurological Diseases
Date/time: Monday, April 29, 2019, 5:00 p.m.
Location: P240, Columbia Hall

Title: “Stability of rAAV Vectors: Response to Various Biochemical and Biophysical Stresses”
Session: Vector and Cell Engineering, Production or Manufacturing
Date/time: Monday, April 29, 2019, 5:00 p.m.
Location: P342, Columbia Hall

Title: “Variability Analysis of qPCR, ddPCR and Potency Assays for AAV Vectors: Implications for Future Development”
Session: RNA Virus Vectors
Date/time: Tuesday, April 30, 2019, 5:00 p.m.
Location: P448, Columbia Hall

Title: “Development of a High Cell Density Perfusion method for Baculovirus Infected Insect Cells (BIICs) Manufacturing”
Session: AAV Vectors III
Date/time: Wednesday, May 1, 2019, 5:00 p.m.
Location: P726, Columbia Hall

Title: “Characterization of AAV Percentage of Full Capsids and Comparability Across Platforms”
Session: AAV Vectors III
Date/time: Wednesday, May 1, 2019, 5:00 p.m.
Location: P743, Columbia Hall

Title: “Optimization and Evaluation of Two Potency Assays for AAV-Based Gene Silencing Programs”
Session: AAV Vectors III
Date/time: Wednesday, May 1, 2019, 5:00 p.m.
Location: P745, Columbia Hall

Title: “Viral Clearance for rAAV Products in a Sf9/Baculovirus Manufacturing Process”
Session: Vector and Cell Engineering, Production or Manufacturing II
Date/time: Wednesday, May 1, 2019, 5:00 p.m.
Location: P899, Columbia Hall

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly-owned and collaborative pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson’s disease, a monogenic form of ALS called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager has strategic collaborations with Sanofi Genzyme, AbbVie and Neurocrine Biosciences. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investor Relations:
Matt Osborne
Vice President of Corporate Affairs, Communications and Investor Relations 
857-259-5353
mosborne@vygr.com

Voyager Media:
Sheryl Seapy 
W2Opure
949-903-4750
sseapy@purecommunications.com

 

 

 

Source: Voyager Therapeutics
3.0
3.0 from 2 votes
Free Newsletter
Trending News
Related Videos
by Abidemi Uruejoma
387 views
by Abidemi Uruejoma
985 views
by Abidemi Uruejoma
11,456 views
by Abidemi Uruejoma
9,828 views